| Tofacitinib in active ulcerative colitis. | |
| | |
MedLine Citation:
|
PMID: 23150971 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
To the Editor: Sandborn et al. (Aug. 16 issue)(1) report that tofacitinib has efficacy in the treatment of ulcerative colitis. The authors note that Janus kinase (JAK) inhibitors JAK1 and JAK3 are surprisingly ineffective in the treatment of Crohn's disease.(2) In Crohn's disease, the major cytokines arise from the differentiation of two subtypes of CD4+ T cells - Th1 and Th17 - whereas in ulcerative colitis a Th2-like differentiation process seems to be involved. Several recent reports on different experimental models seem to indicate that JAK inhibitors such as tofacitinib suppress Th2 but potentiate Th1 and Th17 responses. For example, . . . |
| | |
Authors:
|
Mario Cottone; Ambrogio Orlando; Claudio Papi |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The New England journal of medicine Volume: 367 ISSN: 1533-4406 ISO Abbreviation: N. Engl. J. Med. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0255562 Medline TA: N Engl J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1959-61 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Tofacitinib in active ulcerative colitis.
Next Document: Effect of HIV-2 Infection on HIV-1 Disease Progression.